Skip to content

Research on the evaluation of the clinical efficacy of traditional Chinese medicine in the prevention and treatment of primary liver cancer

Clinical study of patients after radical resection of primary liver cancer with traditional Chinese medicine

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000836
Enrollment
Unknown
Registered
2024-12-17
Start date
2024-11-08
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary liver cancer

Interventions

Primary liver cancer treatment group with integrated traditional Chinese and Western medicine:Ganji particles and basic symptomatic treatment

Sponsors

Anhui Hospital Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Patients with primary liver cancer caused by hepatitis B who meet the above diagnostic criteria; (2) Patients 6 months after radical hepatoctomy (surgery intervention radiofrequency ablation); (3) Age 18~65 years old gender is not limited; (4) Willing to receive TCM and/or integrative treatment; (5) Sign informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with metastatic liver cancer or patients with other tumors; (2) Patients with serious complications such as refractory ascites hepatic encephalopathy liver failure and portal vein embolism; (3) Patients with serious primary diseases of the heart kidney lung endocrine hematologic metabolic and gastrointestinal tract; or spiritual patients; (4) Persons with legal disabilities pregnant or lactating women; (5) Patients with allergies or allergies to multiple drugs.

Design outcomes

Primary

MeasureTime frame
time to progression;Incidence rate ofticompicaons;Postoperative recurrence rate of primary liver cancer;relapse-free survival of primary;1-year survival rate after surgery for primary liver cancer;

Secondary

MeasureTime frame
HBV-DNA;MELD;Child-Pugh;APRI;FIB4;HBV markers;KPS;Quality of Life Core Scale;renal function;imaging examination;bood routine examination;Alpha fetoprotein in primary liver cancer;EORTCQLQ-C30;Lver function;

Countries

China

Contacts

Public ContactZhou Zhenhua

Anhui Hospital Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

jinghua1220@163.com15800586832

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026